Literature DB >> 29532279

Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.

Li Jiang1.   

Abstract

Some fundamental biotechnologies hold unprecedented potential to eradicate many incurable diseases. However, in absence of regulations, the power of patent makes the future use of some important biotechnology in few institution's hands. The excessive patents restrict researcher access to the fundamental technologies. It generates concerns and complaints of deteriorating the public health and social welfare. Furthermore, intellectual curiosities, funding, respect among colleagues etc., rather than patents, are the real motivations driving a major ground-breaking discoveries in biotechnology. These phenomena reveal that some biotechnology patents are alienated from the purpose of patent system. Therefore, it is necessary to take some approaches to stop over-patenting these fundamental biotechnology inventions. This article proposes a model regulatory framework for controlling biotechnology patent alienating from the purpose of patent system.

Keywords:  Alienation; Biotechnology; Justification; Patent

Mesh:

Substances:

Year:  2018        PMID: 29532279     DOI: 10.1007/s11948-018-0043-3

Source DB:  PubMed          Journal:  Sci Eng Ethics        ISSN: 1353-3452            Impact factor:   3.525


  14 in total

1.  Science and law. View from the bench: patents and material transfers.

Authors:  John P Walsh; Charlene Cho; Wesley M Cohen
Journal:  Science       Date:  2005-09-23       Impact factor: 47.728

2.  Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?

Authors:  Maria Auxiliadora Oliveira; Jorge Antonio Zepeda Bermudez; Gabriela Costa Chaves; Germán Velásquez
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

Review 3.  RNA interference (RNAi) patents and human health related applications of RNAi.

Authors:  H Alexander Ebhardt
Journal:  Recent Pat DNA Gene Seq       Date:  2007

4.  Trips and public health: solutions for ensuring global access to essential AIDS medication in the wake of the Paragraph 6 Waiver.

Authors:  Jessica L Greenbaum
Journal:  J Contemp Health Law Policy       Date:  2008

5.  AMP v Myriad: the Supreme Court gives a win to personalized medicine.

Authors:  Roger D Klein
Journal:  J Mol Diagn       Date:  2013-11       Impact factor: 5.568

6.  Trials of embryonic stem cells to launch in China.

Authors:  David Cyranoski
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962

Review 7.  Can patents deter innovation? The anticommons in biomedical research.

Authors:  M A Heller; R S Eisenberg
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

Review 8.  Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.

Authors:  Kirstin R W Matthews; Maude L Cuchiara
Journal:  Regen Med       Date:  2014-03       Impact factor: 3.806

9.  Myriad Genetics: In the eye of the policy storm.

Authors:  E Richard Gold; Julia Carbone
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

10.  Are patents impeding medical care and innovation?

Authors:  E Richard Gold; Warren Kaplan; James Orbinski; Sarah Harland-Logan; Sevil N-Marandi
Journal:  PLoS Med       Date:  2010-01-05       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.